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The  linkage  of  an  immunogen  with  a toll-like  receptor  ligand  has great  potential  to  induce  highly
potent  immune  responses  with  the  initial  features  of  antigen-presenting  cell  activation.  In  the  current
study,  we  expressed  recombinant  dengue-3  envelope  protein  domain  III (D3ED  III) in  lipidated  form
using  an  Escherichia  coli-based  system.  The  recombinant  lipidated  dengue-3  envelope  protein  domain
III (LD3ED  III)  augments  the  expression  levels  of  IL-12  family  cytokines.  LD3ED  III-immunized  mice
enhance  wide  ranges  of  T cell  responses  as indicated  by IFN-,  IL-17,  IL-21  production.  Additionally,
LD3ED  III-immunized  mice  increase  the  frequencies  of  anti-D3ED  III antibody  producing  cells.  The boosted
antibody  titers  cover  various  IgG isotypes,  including  IgG1, IgG2a,  IgG2b,  and  IgG3.  Importantly,  LD3ED
III-immunized  mice  induce  neutralizing  antibody  capacity  associated  with  a reduction  of viremia  levelsipoprotein
accine
after challenges.  In contrast,  mice  that  are  immunized  with D3ED  III formulated  with  aluminum  phos-
phate  (D3ED  III/Alum)  only  enhance  Th2  responses  and  boost  IgG1  antibody  titers.  Neither  neutralizing
antibody  responses  nor  the inhibition  of viremia  levels  after  challenge  is  observed  in  mice that  are  immu-
nized  with  D3ED  III/Alum.  These  results  suggest  that LD3ED  III can  induce  broad  proﬁles  of  cellular  and
humoral  immune  responses.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Dengue fever or severe dengue hemorrhagic fever and dengue
hock syndrome are caused by the infection of dengue virus, which
ncludes four antigenically different serotypes. Although the true
isease burden is not well known, a recent estimation reported
hat dengue infection reaches 390 million clinical infections annu-
lly [1] and results in a serious public health threat in more than
Abbreviations: D3ED III, ecombinant dengue-3 envelope protein domain III; ED
II/Alum, D3ED III formulated with aluminum phosphate; FFU, focus-forming unit;
RNT, focus reduction neutralization tests; IMAC, immobilized metal afﬁnity chro-
atography; LD3ED III, recombinant lipidated dengue-3 envelope protein domain
II.
∗ Corresponding authors at: National Health Research Institutes, NIIDV, No.35,
eyan Road, Zhunan Town 350, Miaoli County, Taiwan. Tel.: +886 930086009;
ax: +886 3 758 3009.
E-mail addresses: leoleng@nhri.org.tw (C.-H. Leng), chenhw@nhri.org.tw
H.-W. Chen).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.vaccine.2016.01.009
264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article
.0/).120 countries throughout tropical and subtropical areas [2,3]. It
is believed that vaccination is an effective and successful tool to
combat pathogens [4]. A licensed dengue vaccine is not currently
available due to the complex interaction of four serotypes of dengue
virus with the human immune system. Pharmaceutical companies
and research laboratories have employed various technologies for
dengue vaccine development. Several dengue vaccine candidates
are in clinical development [5]. The leading vaccine candidate is
Sanoﬁ Pasteur’s live chimeric virus vaccine. After three injections of
tetravalent live chimeric virus vaccine, the vaccine efﬁcacies were
56.5% [6] and 60.8% [7] in Asia and Latin America phase 3 stud-
ies, respectively. Thus, continued efforts are required to develop
dengue vaccines.
Subunit vaccines provide an alternative approach for dengue
vaccine development. Recombinant protein-based subunit vac-
cines do not contain live components of pathogens and are
considered to be safe. In total, recombinant proteins are poor vac-
cine immunogens and require appropriate adjuvants to provoke
the desired immune responses. When designing a subunit vac-
cine, the choice of immunogen is determined by the pathogen,
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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hereas the selection of adjuvant depends on the desired immune
esponse. Dengue envelope protein domain III is a critical region
n the viron surface for viral attachment to cellular receptors [8,9].
everal neutralizing epitopes have been identiﬁed in dengue enve-
ope protein domain III [10–12]. These results suggest that dengue
nvelope protein domain III is a suitable target for dengue vaccine
evelopment [13]. Several dengue envelope protein domain III sub-
nit vaccine candidates have been evaluated in mice [14–21] and
onhuman primates [22–26]. A subunit vaccine candidate formu-
ated with proper adjuvant is required to induce robust immunity.
nfortunately, formulations of dengue subunit vaccines using adju-
ants containing aluminum, the most widely used adjuvants in
uman vaccines, are unable to induce complete protection against
engue virus infection [17,22,25]. Exploring exogenous adjuvant-
ndependent approaches to enhance immunogenicity may  provide
 solution for dengue subunit vaccine design.
An efﬁcient way to trigger immune responses is through the
resentation of the antigen by antigen-presenting cells and simul-
aneously providing activation signals [27,28]. To mimic  natural
nfection, recombinant protein is linked to pattern recognition
eceptor ligands to create immunogen-pattern recognition recep-
or ligand-conjugated subunit vaccines, ensuring that the same
ntigen-presenting cell receives immunogens and stimulation sig-
als at the same time. In our previous studies, we developed a novel
latform technology to express recombinant lipidated immuno-
ens with intrinsic adjuvant properties [29]. The lipid moiety
f recombinant lipidated immunogens provides a danger signal
o activate antigen-presenting cells via toll-like receptor 2 [30]
nd induces an appropriate adaptive immunity in the absence of
xogenous adjuvant formulation [19]. The lipidation strategy has
een applied to dengue-1, -2, and -4 envelope protein domain III
17,18,20,31], but recombinant lipidated dengue-3 envelope pro-
ein domain III (LD3ED III) has not yet been characterized. In the
resent study, we further dissected the proﬁle of T cell and anti-
ody responses in mice that were immunized with LD3ED III. We
onﬁrmed and further extended the main ﬁndings of our previous
orks [17,18,20,31], namely, that recombinant lipidated immuno-
ens can induce strong and persistent immune responses even
ithout formulation with exogenous adjuvants.
. Materials and methods
.1. Virus
Dengue-3/H-087 (laboratory-adapted virus) was used for this
tudy and kindly provided by Dr. Yi-Ling Lin of the Institute of
iomedical Sciences, Academia Sinica, Taiwan. Propagation of virus
as performed in C6/36 cell, and viral titers were determined by
ocus-forming assays with BHK-21 cells [21].
.2. Experimental mice and immunization
Female BALB/c mice were purchased from the National Lab-
ratory Animal Breeding and Research Center (Taipei, Taiwan).
he mice were maintained at the Laboratory Animal Center of
he National Health Research Institutes (NHRI). All of the animal
xperiments were approved and performed in compliance with the
uidelines of the Animal Committee of the NHRI. Groups of mice
6–8 weeks of age) were immunized with D3ED III, D3ED III/Alum,
r LD3ED III via subcutaneous injection. Each mouse received a
0 g/0.2-mL dose. Mice that were immunized with PBS alone
without antigens) served as controls. All of the animals were given injections at a two-week interval with the same regimen. Blood
amples were collected by tail bleeding for 0.1–0.2 mL  from each
ouse at different time points as indicated. The serum samples
ere prepared and stored at −20 ◦C until use.4 (2016) 1054–1061 1055
2.3. Preparation of recombinant proteins and the other materials
and methods
All the details were in Supplementary data.
3. Results
3.1. Preparation and characterization of dengue-3 envelope
protein domain III recombinant immunogens
The dengue-3 envelope protein domain III gene was cloned into
the expression vector pET-22b(+) (Novagen, Madison, WI), using
Nde I and Xho I sites to produce the pD3DEIII plasmid for the
production of recombinant dengue-3 envelope protein domain III
(D3E3 III). To produce LD3ED III, the D3ED III gene was cloned into
the pET-22b-based plasmid containing a lipid signal peptide using
Bam HI and Xho I sites to produce the pLD3EDIII plasmid. As a result,
both D3ED III and LD3ED III were contained an additional HHHHHH
sequence (HisTag) at their C-terminus and were expressed under
the control of the T7 promoter (Fig. 1A).
The D3ED III was puriﬁed using an immobilized metal afﬁn-
ity chromatography (IMAC) column (Fig. 1B, lanes 1–4). D3ED
III was  detected with anti-HisTag antibodies (Fig. 1B, lanes 5–8).
The lipidated counterpart of D3ED III, LD3ED III was also puriﬁed
using an IMAC column (Fig. 1B, lanes 9–12) and was detected with
anti-HisTag antibodies (Fig. 1B, lanes 13–16). After removing the
lipopolysaccharide (LPS), the residues of LPS in D3ED III and LD3ED
III were less than 0.06 EU/mg. To have stable materials for further
characterization and validation, we produced and lyophilized a suf-
ﬁcient amount of materials in one batch. Endotoxin-free D3ED III
and LD3ED III were comparatively analyzed for their immunogenic-
ity and efﬁcacy in animal models.
Next, the exact mass of the N-terminal fragments of LD3ED
III were measured. As shown in Fig. 1C, there were three major
peaks with m/z  values of 1452, 1466, and 1480 in the spectrum.
These peaks have been identiﬁed in other lipidated proteins and
can be considered as a lipidation signature [18,20,29,31,32]. We
conﬁrmed that the peaks of LD3ED III were associated with the
lipidated cysteine residue and veriﬁed that LD3ED III contains a
N-acetyl-S-diacyl-glyceryl-cysteine at its N-terminus.
3.2. Recombinant lipidated dengue-3 envelope protein domain III
upregulates IL-12 family cytokines in bone marrow-derived
dendritic cells
Cytokines are important mediators of immune responses.
Dendritic cells produce IL-12, IL-23, and IL-27 to modulate T cell
differentiation. Members of the IL-12 family are heterodimeric
cytokines that consist of an  chain and a  chain. The p40 chain can
heterodimerize with p35 or p19 to form IL-12 or IL-23, respectively,
whereas Epstein-Barr virus-induced gene 3 (EBI3) can pair with
p28 or p35 to form IL-27 or IL-35, respectively [33]. Therefore, IL-12
family cytokines were analyzed after stimulation. The expression
levels of p40, p35, p19, p28, and EBI3 mRNA in dendritic cells 4 h
after LD3ED III stimulation were higher than PBS stimulated den-
dritic cells for 7180-, 79-, 1895-, 1563-, and 17-fold, respectively
(Fig. 2A). To verify the cytokine expression, heterodimeric form of
IL-12, IL-23, and IL-27 levels in the supernatants were evaluated
by ELISA. As shown in Fig. 2B, the highest levels of IL-12, IL-23,
and IL-27 were induced after LD3ED III stimulation. In contrast,
there were no signiﬁcant IL-12, IL-23, and IL-27 production when
dendritic cells were stimulated with 6 EU/mL LPS (equivalent to
10,000 folds of LD3ED III LPS residues) (Supplementary Fig. 1).
These results indicate that LD3ED III activates dendritic cells and
upregulates the production of IL-12 family cytokines in dendritic
1056 C.-Y. Chiang et al. / Vaccine 34 (2016) 1054–1061
Fig. 1. Production and identiﬁcation of D3E3 III and LD3ED III. (A) Circular map  of plasmid pD3ED III and pLD3ED III for the production of D3ED III and LD3ED III, respectively. (B)
The  puriﬁed D3E3 III protein was  monitored by 15% reducing SDS-PAGE. Coomassie Blue staining was  followed. Anti-HisTag antibodies were used to perform immunoblotting
(lanes  1–8). D3E3 III was  expressed in E. coli strain BL21 (DE3). Lane 1, D3E3 III expression after IPTG induction; lane 2, protein expression in the absence of IPTG induction;
lane  3, soluble fraction of D3E3 III; lane 4, puriﬁed D3E3 III. Lanes 5–8 demonstrate D3E3 III induction and puriﬁcation processes by immunoblotting. The samples in these
lanes  are the same as those in lanes 1–4, respectively. The arrows point the electrophoretic positions of D3E3 III in the gels or blots. The LD3ED III protein puriﬁcation process
was  monitored using 15% reducing SDS–PAGE, followed by staining with Coomassie Blue and immunoblotting using anti-HisTag antibodies (lanes 9–16). LD3ED III was
expressed in E. coli strain C43 (DE3). Lane 9, shows LD3ED III expression after IPTG induction; lane 10, without IPTG induction; lane 11, soluble fraction of LD3ED III; lane 12,
puriﬁed LD3ED III. Lanes 13–16 represent the result of immunoblotting of LD3ED III induction and puriﬁcation processes. Samples in these lanes are the same as those in
lanes  9–12, respectively. The arrows indicate the electrophoretic positions of LD3ED III in the gels or blots. (C) LD3ED III was  digested with trypsin to obtain the N-terminal
LD3ED  III fragments. The digested sample was analyzed on a Waters® MALDI micro MXTM mass spectrometer. The MALDI-TOF MS spectra revealed the presence of three
major  peaks with m/z values of 1452, 1466, and 1480.
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Fig. 2. The expression proﬁle of IL-12, IL-23 and IL-27 in murine bone marrow-derived dendritic cells. Mouse dendritic cells from bone marrow progenitor cells were stimulated
with  10 g of D3ED III, D3ED III/Alum, or LD4ED III in PBS. Dendritic cells that were stimulated with PBS alone (without antigens) served as controls. (A) The cells were
harvested at 0.5, 1, 2, 4, and 6 h post-stimulation. The RNA was  extracted for real-time quantitative PCR analysis. The gene expression was normalized to GAPDH mRNA. The
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ells. These effects are not caused by the trivial LPS residues in
D3ED III.
.3. IFN- and IL-17 are induced in mice that are immunized
ith recombinant lipidated dengue-3 envelope protein domain III
To ascertain whether the expression proﬁles of cytokine genes
n bone marrow-derived dendritic cells associate in vitro with
he immune responses in vivo, we immunized mice with various
ormulations and evaluated the immune responses after immu-
ization. Groups of BALB/c mice were immunized with D3ED III,
D3ED III or D3ED III formulated with aluminum phosphate (D3ED
II/Alum) two times at a two-week interval. The animals that
ere immunized with PBS alone served as negative controls. One
eek after the last immunization, the splenocytes were examinedor cytokine secretion. Fig. 3 shows that supernatants that were
btained from all of the splenocytes produced little levels of IFN-,
L-5, and IL-17 without stimulation (medium alone) or stimulated
ith bovine serum albumin (BSA) for all the time points tested.ected at 6, 8, and 18 h after stimulation. The heterodimeric form of IL-12, IL-23, and
ation from total 6 wells of 2 independent experiments. The statistical signiﬁcance
* p < 0.01.
Remarkably, the supernatants that were obtained from D3ED III-
stimulated splenocytes induced different cytokine proﬁles. The
levels of IFN- and IL-17 were higher in LD3ED III-immunized
mice than in D3ED III-, D3ED III/Alum-, or PBS-immunized mice.
Interestingly, the levels of IL-5 were higher in the mice that were
immunized with D3ED III/Alum than in mice that were immunized
with PBS, D3ED III or LD3ED III. These results suggest that LD3ED
III elicits different cellular immune response proﬁles compared to
D3ED III/Alum.
3.4. Enhanced humoral immunities are induced in mice that are
immunized with recombinant lipidated dengue-3 envelope
protein domain III
IL-21 plays an important role in regulating B cell differenti-
ation, plasma cell generation, and antibody production [34,35].
IL-21-producing cells in spleens were examined by ELISPOT. As
shown in Fig. 4A, the cultured cells without stimulation (medium
alone) or stimulated with BSA did not induced IL-21 secretion.
1058 C.-Y. Chiang et al. / Vaccine 34 (2016) 1054–1061
PBS
D3ED III
LD3ED III
D3ED III/Alum
Day 2A Day 3 Day 4
Medium BSA D3ED III
Stimulation
pg
 / 
m
L
0
1000
2000
3000
Medium BSA D3ED III
Stimulation
0
4000
8000
12000
pg
 / 
m
L
Medium BSA D3ED III
Stimulation
0
3000
6000
9000
pg
 / 
m
L
** **
**
B
Medium BSA D3ED III
Stimulation
pg
 / 
m
L
0
20
40
60
80
Medium BSA D3ED III
Stimulation
0
100
200
300
400
pg
 / 
m
L
Medium BSA D3ED III
Stimulation
0
200
400
600
800
pg
 / 
m
L**
** **
C
Medium BSA D3ED III
Sti mulation
pg
 / 
m
L
0
30
60
90
120
Medi um BSA D3ED III
Sti mulation
0
40
80
120
160
pg
 / 
m
L
Medi um BSA D3ED III
Stimulation
0
100
200
300
400
pg
 / 
m
L
**
**
*
*
Fig. 3. The cytokine production proﬁle in D3ED III- (with or without aluminum phosphate) and LD3ED III-immunized mice. Groups of BALB/c mice were immunized subcutaneously
twice  with 10 g of D3ED III, D3ED III/Alum, or LD4ED III in PBS at a 2-week interval. Mice that were immunized with PBS alone (without antigens) served as controls.
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he  supernatants were collected and used to evaluate the levels of (A) IFN-, (B) I
tatistical signiﬁcance was  determined by Kruskal-Wallis test with Dunn’s multiple
nterestingly, IL-21 secretion was induced in response to D3ED III
timulation in mice that were immunized with LD3ED III but not
ice that were immunized with PBS, D3ED III, or D3ED III/Alum.
he incidence of anti-D3ED III antibody-producing cells following
mmunization with LD3ED III was assessed by ELISPOT. An increase
n anti-D3ED III antibody-secreting cells in bone marrows com-
ared to anti-D3ED III antibody-secreting cells in mice that were
ig. 4. Identiﬁcation of IL-21-producing cells and D3ED III-speciﬁc B cells in D3ED III-(with
ice  were immunized subcutaneously twice with 10 g of D3ED III, D3ED III/Alum, or 
without antigens) served as controls. Splenocytes and bone marrow cells were harvested
3ED  III-speciﬁc antibody-secreting cells in bone marrows and (C) spleens were evaluat
xperiments. The statistical signiﬁcance was determined by Kruskal-Wallis test with Dunltured without stimulation or stimulated with BSA or D3ED III for 2, 3, and 4 days.
d (C) IL-17 by ELISA. Data represent mean ± standard deviation from 4 mice. The
arison test. * p < 0.05. ** p < 0.01.
immunized with PBS, D3ED III, or D3ED III/Alum was  obtained
and was  statistically signiﬁcant (Fig. 4B, p < 0.0001, Kruskal–Wallis
test). The incidence of anti-D3ED III antibody-producing cells in
the spleens presented a similar proﬁle (Fig. 4C). Overall, we con-
cluded that LD3ED III-immunized mice induce IL-21 secretion
and enhance the incidence of B cells to produce anti-D3ED III
antibodies.
 or without aluminum phosphate) and LD3ED III-immunized mice. Groups of BALB/c
LD4ED III in PBS at a 2-week interval. Mice that were immunized with PBS alone
 one week after the second immunization. (A) IL-21-producing cells in spleens, (B)
ed by ELISPOT. Data represent mean ± standard deviation from total 7–8 mice of 2
n’s multiple comparison test. * p < 0.05. ** p < 0.01. *** p < 0.001.
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Fig. 5. Analysis of antibody responses in D3ED III- (with or without aluminum phosphate) and LD3ED III-immunized mice. Groups of BALB/c mice were immunized subcutaneously
twice with 10 g of D3ED III, D3ED III/Alum, or LD4ED III in PBS at a 2-week interval. Mice that were immunized with PBS alone (without antigens) served as controls. The
sera  were collected from mice at the indicated time points after the ﬁrst immunization. (A) Subclasses of anti-D3ED III IgG antibodies and (B) antibody avidity proﬁles were
examined by ELISA. (C) The capacity of dengue-3 virus-neutralizing antibody was  determined by FRNT 8 weeks after the ﬁrst immunization. The neutralizing antibody titer
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The anti-D3ED III IgG subclass proﬁles of serum samples that
ere collected from different groups at weeks 2, 4, and 6 were
xamined. Of the 4 groups of mice, LD3ED III-immunized mice gen-
rated the highest IgG antibody responses for all the subclasses that
e examined. Notably, the mice that were immunized with D3ED
II/Alum increased the anti-D3ED III IgG1 titers but not those of
gG2a, IgG2b, and IgG3 compared to mice that were immunized
ith D3ED III without adjuvant (Fig. 5A). We  next evaluated the
ntibody avidity proﬁles of the serum samples. There was no signif-
cant difference in the avidity index among groups of mice 2 weeks
fter the ﬁrst immunization. After the second immunization, the
vidity index of sera that were obtained from the mice that were
mmunized with LD3ED III quickly increased and was signiﬁcantly
igher than that of the sera that were obtained from the mice that
ere immunized with D3ED III (p < 0.001, Kruskal-Wallis test with
unn’s multiple comparison test). However, the avidity index of the
era that were obtained from the mice that were immunized with
3ED III/Alum was not signiﬁcantly higher than that of the sera
hat were obtained from mice that were immunized with D3ED
II 2 and 4 weeks after booster immunization (Fig. 5B). Altogether,
hese results suggest that LD3ED III can increase the responses of
arious IgG subclasses and enhance antibody afﬁnity.
.5. Lipidated dengue-3 envelope protein domain III induces
eutralizing antibodies and reduces the viremia levels after
hallengeTo determine whether mice that are immunized with LD3ED
II could elicit immunity to blocked viral infection and clear viral
oad in the blood, neutralizing antibody titers induced by vacci-
ation and viremia levels after challenge were examined. Serumto that of the control samples containing the virus alone. The antibody titers were
 deviation from total 8–9 mice of 2 experiments. The statistical signiﬁcance was
 0.01. *** p < 0.001.
samples were collected at weeks 8 after the ﬁrst immunization. The
neutralizing capacity of antibodies was determined by focus reduc-
tion neutralization tests. As shown in Fig. 5C, the mice that were
immunized with D3ED III or D3ED III/Alum could not stimulate
signiﬁcant neutralizing antibody responses (FRNT70 < 8), similar
to mice that were immunized with PBS. In contrast, the mice
that were immunized with LD3ED III elicited low but moderate
neutralizing antibody responses (average FRNT70 = 12.7) (p < 0.001,
Kruskal–Wallis test). Next, all of the immunized mice were chal-
lenged with dengue-3-infected K562 cells 20 weeks after the ﬁrst
immunization. The viremia levels of mice that were immunized
with D3ED III or D3ED III/Alum were equivalent to those of mice
that were immunized with PBS at all of the time points that we
examined. Although the viral loads in the blood of LD3ED III-
immunized mice were comparable to the other vaccinated mice
8 h after challenge, the viremia levels of LD3ED III-immunized mice
quickly decreased and were signiﬁcantly lower than those the other
vaccinated mice 22 (p < 0.01, Kruskal–Wallis test) and 32 (p < 0.05,
Kruskal–Wallis test) hours after challenge (Fig. 6). Collectively, our
results suggest that LD3ED III induces neutralizing antibodies and
reduces the viremia levels after challenge in mice.
4. Discussion
The development of an effective vaccine that induces a broad
and durable adaptive immunity against pathogens is still a serious
challenge. The present study, using LD3ED III, has demonstrated
that immunogens that are expressed in lipidated form to activate
antigen-presenting cells provide an attractive strategy for modu-
lating immune responses and have the potential to enhance the
efﬁcacy of vaccines.
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Fig. 6. Inhibition of viremia levels in LD3ED III-immunized mice. BALB/c mice were
immunized subcutaneously twice with 10 g of D3ED III, D3ED III/Alum, or LD3ED III
in  PBS at a 2-week interval (5 mice for each group). Mice that were immunized with
PBS  alone (without antigens) served as controls. Twenty weeks after the ﬁrst immu-
nization, the mice were intraperitoneally challenged with dengue-3-infected K562
cells. The mice were bled after challenge at the indicated time points (n = 5 for each
time point). The plasma viral titers were determined by focus-forming assays using
BHK-21 cells. The viremia levels were logarithmically transformed before statistical060 C.-Y. Chiang et al. / Va
The initial adaptive immune responses are triggered by pro-
essional antigen-presenting cells. Dendritic cells are the most
otent antigen-presenting cells to activate naïve T cells [36]. Upon
ctivation, dendritic cells can produce different cytokines depend-
ng on the stimuli to modulate immune responses. IL-12, IL-23,
nd IL-27, the members of the IL-12 cytokine family that are
roduced by dendritic cells, are particularly inﬂuential in deter-
ining the fate of T cells [33]. We  demonstrate that LD3ED
II induces the upregulation of all of the components of IL-12
ytokine family mRNA (Fig. 2A). Importantly, IL-12, IL-23, and
L-27 levels in the supernatants are augmented under the stim-
lus of LD3ED III (Fig. 2B). IL-12 and IL-23 are key cytokines in
acilitating Th1 differentiation [37] and supporting Th17 expan-
ion [38], respectively. In agreement with these ﬁndings, mice
hat are immunized with LD3ED III elicit IFN- and IL-17 pro-
uction (Fig. 3), which are the signature cytokines of the Th1
nd Th17 response, respectively. Many studies have reported that
L-27 acts to constrain inﬂammation in most cases. However,
L-27 plays a proinﬂammatory role in some circumstances [39].
L-27 facilitates the development of follicular helper T cells via
he induction of IL-21 [40]. IL-21 can also act as an autocrine
rowth factor for follicular helper T cells [41,42]. In the present
tudy, IL-21-producing cells were induced in mice that were
mmunized with LD3ED III but not D3ED III or D3ED III/Alum
Fig. 4A). Altogether, these ﬁndings suggest that recombinant
ipidated immunogen stimulates antigen-presenting cells to upreg-
late IL-12, IL-23, and IL-27 production. Under these conditions, the
evelopment of Th1, Th17, and follicular helper T cells is efﬁciently
romoted.
The follicular helper T cell-derived IL-21 provides crucial sig-
als to modulate the development and function of B cells [43,44].
he IL-27-IL-21 axis is important for the germinal center func-
ion and development of T cell-dependent antibody responses
40]. Germinal centers are the sites of B cell clonal expansion,
omatic hypermutation, and afﬁnity maturation, the combina-
ion of which results in the production of high-afﬁnity antibodies
45]. The afﬁnity of antibodies in mice that were immunized with
D3ED III was quickly increased and higher than that in mice
hat were immunized with D3ED III formulated with or with-
ut aluminum phosphate (Fig. 5B). These results indicate that
D3ED III-immunized mice build a favorable environment for B
ell afﬁnity-based selection. Antibodies are secreted by plasma
 cells. The long-lived plasma B cells migrate to the bone mar-
ow, which is responsible for long-term humoral immunity [46].
otable frequencies of D3ED III-speciﬁc antibody-secreting cells
re present in the bone marrow and spleen of LD3ED III-immunized
ice (Fig. 4B and C). In addition, a comprehensive enhancement of
ntibody responses is induced in mice that are immunized with
D3ED III. The elevation of antibody titers is not limited to IgG1 but
lso other IgG isotypes, including IgG2a, IgG2b, and IgG3 (Fig. 5A).
igh IgG1 titers for the dengue envelope protein domain III have
een shown in mice immunized with subunit vaccines. Interest-
ngly, low titers of IgG3 against dengue envelope protein domain III
ere only detected in mice after immunization with dengue virus
16,47]. These results suggest that LD3ED III elicits a much more
iverse IgG subclass response which is similar to dengue virus. In
ontrast, mice that are immunized with D3ED III/Alum induce the
roduction of IL-5, a Th2 cytokine (Fig. 3), and only enhance IgG1
ntibody responses (Fig. 5A). Associated with these ﬁndings with
ur cytokine results in dendritic cells and T cells, mice that are
mmunized with LD3ED III should promote the efﬁcient produc-
ion of anti-D3ED III-speciﬁc antibodies. We  conclude that mice
hat are immunized with LD3ED III not only increase the intensity
f antibody responses (antibody titers) but also broaden the pro-
le of antibody responses (IgG isotypes) and enhance the antibody
fﬁnity.analyses. Data represent the mean ± standard deviation. The statistical signiﬁcance
was determined by Kruskal–Wallis test with Dunn’s multiple comparison test. **
p  < 0.01.
Mice immunized with LD3ED III induced low neutralizing anti-
body titers (average FRNT70 = 12.7) at 8 weeks after the ﬁrst
immunization (Fig. 5C). However, high levels of anti-D3ED III IgG
antibodies were elicited (Fig. 5A). This phenomenon is similar to
mice immunized with recombinant lipidated dengue-4 envelope
protein domain III (LD4ED III) [31]. It is possible that neutraliz-
ing epitopes are not dominant in D3ED III and D4ED III. In general,
laboratory strains of immunocompetent mice are not susceptible
to clinical diseases. Dengue viral infection may  produce viremia
in some immunodeﬁciency mice. Because immunodeﬁciency mice
lack for a normal immune system, they are not suitable for vaccine
evaluation. Recently, Yamanaka and Konishi developed a simple
model for dengue vaccine evaluation using dengue-infected cells
to challenge immunocompetent mice [48]. Thus, we  adopted this
dengue viral challenge model. Results in the challenge experiments
indicate that mice immunized with LD3ED III have better capability
of clearance of viral load in the blood than mice immunized with
PBS, D3ED III, or D3ED III/Alum (Fig. 6).
Effective vaccination should induce protective immunity.
Although D3ED III/Alum can enhance the Th2 response and IgG1
titers, no signiﬁcant neutralizing capacity (Fig. 5C) or inhibition
of viremia were generated (Fig. 6). Remarkably, LD3ED III in the
absence of exogenous adjuvant can induce neutralizing antibody
responses and reduce viremia levels after challenge. Collectively,
LD3ED III alone is able to nourish potent immunity. Subunit vac-
cines may  have some advantages over other vaccine approaches.
In general, the major weakness of subunit vaccine is low immuno-
genicity. An adjuvant is necessary to enhance immune responses.
The likely problem does not seem insurmountable, and many
solutions could emerge from a detailed study of the lipidated
immunogens. Our results suggest that the use of recombinant lip-
idated immunogens to enhance immunity and improve subunit
vaccines therefore has sufﬁcient promise to justify further detailed
clinical studies.Conﬂict of interest statement
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